Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography

New England Journal of Medicine

Volumn 335, Issue 13, 1996, Pages 919-923

  Cavallini, Giorgio ^a,c   Tittobello, Alberto ^b   Frulloni, Luca ^a   Masci, Enzo ^b   Mariani, Alberto ^b   Di Francesco, Vincenzo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c POLICLINICO BORGO ROMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; GABEXATE; GABEXATE MESILATE; MANNITOL; PLACEBO; SODIUM CHLORIDE; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADULT; AGED; AMYLASE BLOOD LEVEL; ARTICLE; CHOLANGITIS; CLINICAL TRIAL; COMMON BILE DUCT STONE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPNEA; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SPHINCTEROTOMY; FEMALE; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PANCREAS INJURY; POSTOPERATIVE ANALGESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VATER PAPILLA STENOSIS; VOMITING;

ACUTE DISEASE; ADULT; AGED; AMYLASES; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DOUBLE-BLIND METHOD; FEMALE; GABEXATE; HUMANS; LIPASE; MALE; MIDDLE AGED; PANCREATITIS; SERINE PROTEINASE INHIBITORS;

EID: 0029788508     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199609263351302     Document Type: Article

References (35)

1. Skude G, Wehlin L, Maruyama T, Ariyama J. Hyperamylasaemia after duodenoscopy and retrograde cholangiopancreatography. Gut 1976;17: 127-32.
2. LaFerla G, Gordon S, Archibald M, Murray WR. Hyperamylasaemia and acute pancreatitis following endoscopic retrograde cholangiopancreatography. Pancreas 1986;1:160-3.
3. Vaira D, D'Anna L, Ainley C, et al. Endoscopic sphincterotomy in 1000 consecutive patients. Lancet 1989;2:431-4.
4. Sherman S, Lehman GA. ERCP- and endoscopic sphincterotomy-induced pancreatitis. Pancreas 1991;6:350-67. [Erratum, Pancreas 1992;7: 402.]
5. Chen YK, Foliente RL, Santoro MJ, Walter MH, Collen MJ. Endoscopic sphincterotomy-induced pancreatitis: increased risk associated with nondilated bile ducts and sphincter of Oddi dysfunction. Am J Gastroenterol 1994;89:327-33.
6. Sherman S. ERCP and endoscopic sphincterotomy-induced pancreatitis. Am J Gastroenterol 1994;89:303-5.
7. Koch H, Belohlavek D, Schaffner O, Tympner F, Rösch W, Demling L. Prospective study for the prevention of pancreatitis following endoscopic retrograde cholangio-pancreatography (ERCP). Endoscopy 1975;7:221-4.
8. Silvis SE, Vennes GA. The role of glucagon in endoscopic cholangiopancreatography. Gastrointest Endosc 1975;21:162-3.
9. Odes HS, Novis BN, Barbezat GO, Banks S. Effect of calcitonin on the serum amylase levels after endoscopic retrograde cholangiopancreatography. Digestion 1977;16:180-4.
10. Sand J, Nordback I. Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography. Digestion 1993;54:105-11.
11. Börsch G, Bergbauer M, Nebel W, Sabin G. Der Einfluss von Somatostatin auf die Amylasespiegel und Pankreatitisrate nach ERCP. Med Welt 1984;35:109-12.
12. Bordas JM, Toledo V, Mondelo F, Rodes J. Prevention of pancreatic reactions by bolus somatostatin administration in patients undergoing endoscopic retrograde cholangio-pancreatography and endoscopic sphincterotomy. Hormone Res 1988;29:106-8.
13. Saari A, Kivilaakso E, Shroder T. The influence of somatostatin on pancreatic irritation after pancreatography: an experimental and clinical study. Surg Res Commun 1988;24:271-4.
14. Testoni P, Masci E, Bagnolo F, Tittobello A. EndoscopiC papillosphincterotomy: prevention of pancreatic reaction by somatostatin. Ital J Gastroenterol 1988;20:70-3.
15. Binmoeller KF, Harris AG, Dumas R, Grimaldi C, Delmont JP. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? Gut 1992;33:1129-33.
16. Sternlieb JM, Aronchick CA, Retig JN, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992;87:1561-6.
17. Arcidiacono R, Gambitta P, Rossi A, Grosso C, Bini M, Zanasi G. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy 1994;26: 715-8.
18. 1 esterase. Biochim Biophys Acta 1977;484:417-22.
19. Nishijima MK, Takezawa J, Taenaka N, Shimada Y, Yoshiya I. Application of HPLC measurement of plasma concentration of gabexate mesilate. Thromb Res 1983;31:279-84.
20. Ohshio G, Saluja AK, Leli U, Sengupta A, Steer ML. Esterase inhibitors prevent lysosomal enzyme redistribution in two noninvasive models of experimental pancreatitis. Gastroenterology 1989;96:853-9.
21. Niederau C, Liddle RA, Ferrell LD, Grendell JH. Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice: evidence for cholccystokinin as a major factor in the development of acute pancreatitis. J Clin Invest 1986;78:1056-63.
22. Wisner JR Jr, Renner IG, Grendell JH, Niederau C, Ferrell LD. Gabexate mesilate (FOY) protects against ceruletide-induced acute pancreatitis in the rat. Pancreas 1987;2:181-6.
23. Wakayama T, Itoh T, Shibayama K, Idezuki Y. Prevention of the spread of experimental acute pancreatitis by intraductal administration of a synthetic inhibitor in dogs. Am J Gastroenterol 1989;84:272-8.
24. Kuno N, Kasugai T, Oguri T, et al. Study on prevention of complications associated with endoscopic retrograde cholangiopancreatography (ERCP): a controlled trial of a new protease inhibitor, Foy, in hyperamylasemia following endoscopic retrograde cholangiopancreatography. Gendai Iryo 1978;10:571.
25. Inada Y, Yamada M, Kadohara M, et al. The clinical study on the effect of Foy on complications following endoscopic retrograde cholangiopancreatography. Gendai Iryo 1980;12:1493.
26. Tsunashima T, Kawai K, Suwaki K, et al. Experience with Foy for the prevention of acute pancreatitis after ERCP Gendai Iryo 1979;11:543.
27. Matsunaga E, Sato J, Nakashima H, et al. Effect of Foy on prevention of the occurrence of pancreatitis after ERCP Gendai Iryo 1979;11: 1213.
28. Salomon V, Kuntz HD, May B. Wirkung des synthetischen protcinase-inhibitors Foy auf die hyperamilasämie nach ERCP. In: Grozinger KH, Schrey A, Wabnitz RW, eds. Proteinasen inhibition, Foy workshop, Düsseldorf 1981. Munich, Germany: Wolf & Sohn, 1982:132-5.
29. Benini L, Angelini G, Lavarini E, et al. Effect of a new enzyme inhibitor (gabexate mesilate-FOY) on hyperenzymemia induced by ERCP: a double-blind study. Digestion 1985;32:165. abstract.
30. Büchler M, Malfertheiner P, Uhl W. Gabexate mesilate in human acutepancreatitis. Gastroenterology 1993;104:1165-70.
31. Pederzoli P, Cavailini G, Falconi M, Bassi C. Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.PA): a prospective, randomized, double-blind multicenter study. Int J Pancreatol 1993;14:117-24.
32. Sherman S, Hawes RH, Rathgaber SW, et al. Post-ERCP pancreatitis: randomized, prospective study comparing a low- and high-osmolality contrast agent. Gastrointest Endosc 1994;40:422-7.
33. Blackwood WD, Vennes JA, Silvis SE. Post-endoscopy pancreatitis and hyperamylasuria. Gastrointest Endosc 1973;20:56-8.
34. Saluja A, Saluja M, Villa A, et al. Pancreatic duct obstruction in rabbits causes digestive zymogen and lysosomal enzyme colocalization. J Clin Invest 1989;84:1260-6.
35. Ohshio G, Saluja A, Steer ML. Effects of short-term pancreatic duct obstruction in rats. Gastroenterology 1991;100:196-202.